Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jeremy Holter

Internal Medicine Shawnee, OK Medical Doctor

NPI 1003859778 CMS profile 45467

3315 Kethley Rd, Shawnee, OK 74804

Open in the dashboard

General payments

$2,979

178 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jeremy Holter of Shawnee, OK is reported in the CMS Open Payments database as having received $2,979 across 178 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,146 63
2024 General $806 44
2023 General $496 33
2022 General $471 34
2021 General $60 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeremy Holter
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Jeremy Holter were reported at $1,146. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Jeremy Holter Internal Medicine median Middle half National median
2019 $0 $159 $48–$570 $163
2020 $0 $119 $33–$402 $114
2021 $60 $135 $37–$521 $132
2022 $471 $141 $42–$496 $149
2023 $496 $149 $45–$519 $160
2024 $806 $154 $47–$537 $164
2025 $1,146 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,135 84 payments
  2. AstraZeneca Pharmaceuticals LP $458 18 payments
  3. Lilly USA, LLC $351 21 payments
  4. Pfizer Inc. $163 9 payments
  5. Amgen Inc. $131 7 payments
  6. ITI, Inc. $127 6 payments
  7. Corium, Inc. $99 4 payments
  8. Sumitomo Pharma America, Inc. $68 3 payments
  9. GlaxoSmithKline, LLC. $68 4 payments
  10. Antares Pharma, Inc. $58 3 payments
  11. Other $320 19 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,979 178 payments
Products named General payments · program years 2021–2025
  1. QULIPTA $421 26 payments
  2. VRAYLAR Neuroscience $420 32 payments
  3. BREZTRI $354 11 payments
  4. UBRELVY $315 17 payments
  5. MOUNJARO $278 16 payments
  6. AIRSUPRA $181 8 payments
  7. Otezla $131 7 payments
  8. CAPLYTA $127 6 payments
  9. NURTEC ODT $125 7 payments
  10. VRAYLAR Neuroscience $116 14 payments
  11. Other $1,353 74 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 159 drugs

Part D claims

10,559

Median for Internal Medicine: 777

Drug cost

$711,065

Median for Internal Medicine: $73,373

Branded share of claims

20.5%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 118 $129,477
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 98 $92,246
Eliquis Apixaban Brand 75 $62,359
Jardiance Empagliflozin Brand 29 $42,614
Xarelto Rivaroxaban Brand 56 $41,249
Mounjaro Tirzepatide Brand 37 $38,498
Tresiba Flextouch U-200 Insulin Degludec Brand 16 $20,520
Rybelsus Semaglutide Brand 13 $20,312
Januvia Sitagliptin Phosphate Brand 21 $18,997
Arexvy Rsvpref3 Antigen/As01e/Pf Brand 61 $17,725

The 10 drugs with the highest cost, of 159 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 49 billing codes

Paid by Medicare

$97,135

Of which drugs: $36,759

Medicare patients

326

Average age 76

Services billed

2,265

179 women, 147 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Diabetes 35%
Ischemic heart disease 34%
COPD 21%
Chronic kidney disease 20%
Atrial fibrillation 18%
Heart failure 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Sarscov2 vac 50 mcg/0.5ml im 91322 Office 78 78 $12,357
Vaccine for influenza for injection into muscle 90662 Office 119 122 $9,893
Pcv20 vaccine im 90677 Office 15 15 $4,335
Sarscv2 vac 30mcg trs-suc im 91320 Office 27 27 $3,518

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $143
$143 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $114
$114 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $111
$111 — —
QULIPTA
  • AbbVie, Inc. $94
$94 — —
UBRELVY
  • AbbVie, Inc. $56
$56 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

178 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record